Finance

AstraZeneca buys drugmaker Caelum in deal worth up to $500 mln

Above Article Content Ad

The emblem for AstraZeneca is seen outdoors its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Picture

Sept 29 (Reuters) – AstraZeneca stated on Wednesday its newly acquired Alexion division will buy the remaining fairness in drugmaker Caelum Biosciences in a deal that may very well be price as much as $500 million, increasing its entry into rare-disease remedies.

The Anglo-Swedish drugmaker stated it will take ahead Caelum’s late-stage trial of a possible drugs to deal with AL amyloidosis, a uncommon illness that impacts the center, kidneys and different organs.

Reporting by Yadarisa Shabong in Bengaluru; Enhancing by Sherry Jacob-Phillips

:

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button